RESILIENT

• Research type

  Research Study

• Full title

  RESILIENT: RandomisEd, controlled, double blind Study to assess mechanistic effects of combination therapy of dapagliflozin with Exenatide QW versus dapagliflozin alone in obese (BMI>30 kg/m2) patients with Type 2 diabetes mellitus

• IRAS ID

  169304

• Contact name

  Daniel Cuthbertson

• Contact email

  daniel.cuthbertson@liv.ac.uk

• Sponsor organisation

  University of LIverpool

• Eudract number

  2015-005242-60

• Duration of Study in the UK

  3 years, 0 months, 0 days

• Research summary

  This is a randomised, controlled, double blind Study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese (BMI>30 kg/m2) patients with Type 2 diabetes mellitus.

• REC name

  North West - Liverpool Central Research Ethics Committee

• REC reference

  16/NW/0496

• Date of REC Opinion

  17 Aug 2016

• REC opinion

  Further Information Favourable Opinion